Patent application number | Description | Published |
20090170890 | METHOHDS OF INHIBITING VIRAL INFECTION - A method of inhibiting viral infection in a mammal in need of same, includes administering an effective amount of at least one of the compounds of FGI-103 which are represented by 273, 365 and 510 either prophylactically to prevent viral infection, or therapeutically following viral infection. These compounds appear to selectively inhibit Caspase 8 as a method of preventing infective viral particle release. They can be administered IV, IP, orally or via other conventional administration routes. The compounds are highly effective, requiring relatively low dosages on the order of 1 ng/kg-200 mg/kg of body weight. | 07-02-2009 |
20090186041 | ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS - The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection. | 07-23-2009 |
20090220527 | AFFINITY OPTIMIZED EPHA2 AGONISTIC ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy. | 09-03-2009 |
20090285819 | METHODS AND COMPOSITIONS FOR TREATING INFLUENZA - Genes relating to resistance to infection by influenza virus are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used for the prevention and treatment of influenza. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. | 11-19-2009 |
20100286248 | HUMAN FG01 GENE AND ITS APPLICATIONS - A human gene, fg01, on chromosome 8, is identified. This gene, and its expression product, human fg01, shares a homology under 70% with the corresponding murine gene, which has been linked to presentation of the Alzheimer's phenotype of Aβ plaques and hyperphosphorylated tau tangles. Upregulation appears to suppress the Alzheimer's phenotype, which may be effective in preventing the onset of symptoms or progression of symptoms associated with AD. Screening methods are also set forth. | 11-11-2010 |
20100286252 | HUMAN FG01 GENE AND ITS APPLICATIONS - A human gene, fg01, on chromosome 8, is identified, as well as a truncated form on chromosome 5. Upregulation appears to suppress the Alzheimer's phenotype, (AB plaques and hyperphosphorylated tau tangles) which may address the onset of symptoms or progression of symptoms associated with AD. Screening methods are also set forth. | 11-11-2010 |
20110152343 | PROTEASE INHIBITORS AND BROAD-SPECTRUM ANTIVIRAL - Caspace inhibition provides inhibition of viral infection across a wide collection of caspaces and viruses. Caspace inhibition, the prevention of the formation of active caspaces, can be achieved either through gene therapy, protein binding an inhibition, or through small molecule administration. Examples for small molecule inhibition allow the formation of a pharmacaphore to identify more and more active small molecules. | 06-23-2011 |
20110206695 | ANTIBODIES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PROSTATE CANCER - XMRV appears to be related to both prostate cancer if it infects a male germ cell and chronic fatigue syndrome in both sexes. (If the virus does not infect a germ cell). Prostate cancer cells exhibit TSG101 on the surface only upon infection with a virus like XMRV. Antibodies to TSG101 can be effective diagnostics to identify individuals with a predisposition to prostate. They can also be used in place of current diagnostics to confirm the presence of prostate cancer. TSG101 antibodies, when administered in vivo, exhibit the ability to reduce tumor size, suppress metastatic transformation and extend survival. | 08-25-2011 |
20110287019 | THERAPEUTIC TARGETING OF ESCORT PROTEINS - The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein like Tsg101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse. | 11-24-2011 |
20120142731 | METHODS OF INHIBITING VIRAL INFECTION - Compounds, pharmaceutical compositions and methods of inhibiting viral infection in a mammal in need of same, are provided, which employ compounds of the formula | 06-07-2012 |